Synribo
Total Payments
$1.1M
Transactions
40
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $66,545 | 2 | 0 |
| 2023 | $299,453 | 9 | 0 |
| 2022 | $408,744 | 13 | 0 |
| 2021 | $123,429 | 5 | 0 |
| 2020 | $169,392 | 5 | 0 |
| 2018 | $80,036 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 40 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase Ib/II study of omacetaxine and venetoclax for patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome harboring mutant RUNX1 | Teva Pharmaceuticals USA, Inc. | $358,320 | 0 |
| VEN-OM: Phase IB/II Study Of Safety And Efficacy Of Venetoclax When Combined With Escalating Doses Of Omacetaxine In Patients With Relapsed/Refractory Hematologic Malignancies Failing Treatment With Venetoclax-Containing Regimens | Teva Pharmaceuticals USA, Inc. | $207,224 | 0 |
| Patient-centered approach to elicit and compare the treatment goals of patients with episodic and chronic migraine and healthcare providers | Teva Pharmaceuticals USA, Inc. | $150,754 | 0 |
| A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure | Teva Pharmaceuticals USA, Inc. | $96,000 | 0 |
| Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients with Previously Untreated High Grade Myelodysplastic Syndromes | Teva Pharmaceuticals USA, Inc. | $83,065 | 0 |
| VEN-OM: Phase IB/II Study Of Safety And Efficacy Of Venetoclax When Combined With Escalating Doses Of Omacetaxine In Patients With Relapsed/Refractory Hematologic Malignancies Failing Treatment With Venetoclax-Containing Regimens _ | Teva Pharmaceuticals USA, Inc. | $56,604 | 0 |
| Omacetaxine Mepesuccinate with Azacitidine for Patients with Previously Untreated Higher Risk Myelodysplastic Syndrome | Teva Pharmaceuticals USA, Inc. | $48,928 | 0 |
| A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure | Teva Pharmaceuticals USA, Inc. | $46,349 | 0 |
| Studies to determine the pre-clinical in vivo efficacy of Omecetaxine against human AML xenograft expressing mutant RUNX1. | Teva Pharmaceuticals USA, Inc. | $33,360 | 0 |
| Patient-centered approach to elicit and compare the treatment goals of patients with episodic and chronic migraine and healthcare providers_ | Teva Pharmaceuticals USA, Inc. | $33,308 | 0 |
| Phase IB/II Study of Omacetaxine with Cytarabine and Idarubicin Induction Therapy for Patients with de novo Acute Myelogenous leukemia | Teva Pharmaceuticals USA, Inc. | $29,046 | 0 |
| An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose inPatients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies | Teva Pharmaceuticals USA, Inc. | $4,641 | 0 |
Top Doctors Receiving Payments for Synribo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $1.1M | 40 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 40
About Synribo
Synribo is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 40 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2024. In 2024, $66,545 was paid across 2 transactions to 0 doctors.
The most common payment nature for Synribo is "Unspecified" ($1.1M, 100.0% of total).
Synribo is associated with 12 research studies, including "Phase Ib/II study of omacetaxine and venetoclax for patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome harboring mutant RUNX1" ($358,320).